Negative hyperselection of patients with stage III colon cancer receiving anti-EGFR-based adjuvant treatment.

This improvement, however, did not reach statistical significance in the overall population ( P = 0.28) or in patients with distal primary tumors ( P = 0.15), likely due to the post hoc nature of the analysis and limited statistical power in small number subgroups.

also in 111,027 other papers

In the curative setting, a post hoc analysis of the PETACC-8 clinical trial testing adjuvant FOLFOX ± cetuximab in stage III CC showed a trend toward better survival outcomes with FOLFOX + cetuximab compared with FOLFOX alone in patients selected for the absence of extended RAS ( KRAS and NRAS exon 2, 3, 4) and BRAF (exons 11 and 15) mutations. 26 We hypothesize that extending the paradigm of negative hyperselection in stage III CC patients enrolled in the PETACC-8 clinical trial beyond RAS/BRAF by means of a simplified PRESSING panel, in addition to MSI status and primary tumor location selection, may identify a subgroup deriving greater benefit from anti-EGFR agents also in the adjuvant setting.

also in 53,322 other papers